1. Urinary iron excretion after desferrioxamine has been examined in nine patients with different iron-loading anaemias. Particular attention has been paid to individual variation in response and the kinetics of iron removal in order to determine the most efficient and convenient method of administration.
Introduction
Patients with genetic or acquired anaemias who require regular blood transfusion may become iron loaded and develop cardiac, hepatic and endo crine damage (Ellis, Schulman & Smith, 1954; Fink, 1964; Buja & Roberts, 1971) . On a world scale this problem is seen most commonly in thalassaemia, where heart failure and arrhythmias due to iron loading are the usual causes of death in the second or third decades (Engle, 1964) . In some patients increased gastrointestinal iron absorption is a major additional factor in iron loading, and intake from both sources may be up to 20 mg daily (Modell & Beck, 1974) .
Improved survival and reversal of some of the pathological changes of iron overload has been reported in patients with haemochromatosis who are treated by regular venesection (Weintraub, Conrad & Crosby, 1966; Bomford & Williams, 1976) . This approach is not feasible in iron-loading anaemias and the use of iron-chelating agents of various effectiveness and toxicity has been explored (Waxman & Brown, 1969) . Desferrioxamine has proved most effective and least toxic. However, its administration by daily intramuscular injection has proved disappointing and the amount of iron excreted has been barely sufficient to obtain negative iron balance except in cases with a severe 100 M. J. Pippard, S. T. Callender & D. J. Weatherall iron load (Modell & Beck, 1974) . Nevertheless, a long-term trial has suggested that even with such inadequate chelation therapy there may be a delay in the progression of pathological changes (Barry, Flynn, Letsky & Risdon, 1974) , though it has not been possible to demonstrate any effect on cardiac function or length of survival.
Early studies of the pharmacology of desferriox amine hinted that prolonged intravenous infusions might produce better yields of iron than bolus injections (Smith, 1964) . Much larger doses than those possible with intramuscular injections, amounting to 16 g in 24 h, have been given in this way, with total urinary iron excretion rising to amounts as high as 190 mg (Modell & Beck, 1974) . Renewed interest in this approach followed a report of an approximately threefold increase in urinary iron yields by use of continuous intravenous infusions, as compared with intramuscular injec tions of the same dose in two thalassaemic children (Propper, Shurin & Nathan, 1976) . It was also shown that 24 h subcutaneous infusions were superior to intramuscular bolus injections (Prop per, Nathan, Cooper, Rufo, Hussain, Flynn, Green, Hussein & Hoffbrand, 1976) .
We have attempted to define the most effective way of giving desferrioxamine to patients with a variety of iron-loading anaemias. We have com pared bolus injections and various lengths of infusions, examined the pattern of urinary iron excretion with different routes of administration, and evaluated the use of ascorbic acid as an adjuvant to this therapy.
Methods
Details of the nine patients studied are shown in Table 1 . Previous intramuscular injections of desferrioxamine had been given regularly only to MK (from the age of 14 years) and RC (from the age of 7 years), though AS and CC had received them for short periods. EP and TT had been given 1-2 g of desferrioxamine with each blood trans fusion. Patients on regular transfusion were studied midway between transfusions. Desferrioxamine mesylate (Ciba) was diluted, 500 mg in 2 ml of water, for intramuscular and subcutaneous bolus injections. Intravenous and subcutaneous infusions were given through a 23-gauge cannula connected by narrow-bore tubing to a Handley clockwork infusion pump, delivering either 1 or 2 ml/h of suitable dilutions in water. Doses of up to 6 g in 12 h could be given with this equipment, but in practice an infusion dose rate of 4 g in 12 h was rarely exceeded. This represented 62-5 mg/kgin the heaviest patient (CC) and 222 mg/kg in the lightest (EP). Subcutaneous infusions were given into the anterior abdominal wall. Urine was collected into iron-free containers in timed fractions for at least 24 h after bolus injections or 12 h infusions, and for at least 36 h after 24 h infusions. Urinary iron was measured with a Perkin-Elmer atomic absorption spectrophotometer (Zettner & Mansbach, 1965 
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101 haematological values were measured before and after the period of study by standard laboratory techniques. Ascorbate concentrations were measured by a fluorimetric method (Hubmann, Monnier & Roth, 1969 ) modified for both leucocyte and plasma estimations. Three patients (TT, AS and RC) were taught to give regular subcutaneous infusions to themselves at home. Ophthalmological examination was performed at intervals to detect any possible early cataract formation with prolonged use of desferrioxamine in high doses.
Results

Comparison of bolus injections and infusions
Intramuicular and subcutaneous bolus injections of the same dose of desferrioxamine gave similar urinary iron excretions in six patients (Table 2) . Results with intravenous and subcutaneous in fusions were comparable in patients EP, RC and AS, but in a fourth patient, CC, the subcutaneous route gave a rather better iron excretion than the intravenous. Subcutaneous infusions over 12 h in all*nine patients gave a mean increase of 64% (range 20-125%) over that obtained with an intra muscular bolus injection of the same dose.
Dose/response relationship with 12 h subcutaneous infusions
Increasing doses given as subcutaneous infusions over 12 h produced a linear dose/urinary iron excretion relationship, followed by a tendency to reach a plateau at higher doses ( Fig. 1 ). There was marked variation between patients in the amount of urinary iron excreted for a given infusion dose. This could not be predicted by the age, weight or estimated iron load, and was not significantly correlated with serum ferritin concentrations even if doses and iron excretions were expressed in mg/kg body weight. In response to 2 g in 12 h one of the highest iron excretions (60 mg) was seen in one of the youngest patients (SM), whereas an older patient (TT), who had received many more blood transfusions, produced rather less urinary iron (28 mg). In spite of receiving regular intramuscular desferrioxamine injections for 9 years, MK excreted iron equivalent to that in 330 ml of blood with a single 12 h infusion of 4 g.
Patterns of urinary iron excretion
Values are given as mean ± 1 SD. With intra muscular bolus injections 63% ± 11-5% (κ = 9) of the 24 h urinary iron excretion occurred in the first 6 h. The corresponding figure for subcutaneous bolus injection was 58% ± 14-3% (n = 5). With a total of 29 12 h subcutaneous infusions given over a range of doses to nine patients 21-8% ± 7-0% of the 24 h urinary iron excretion occurred in the first 6 h, rising to 63· 7% ± 10-8% at 12 h. A similar pattern was seen with 12 h intravenous infusions and was. the same in all patients and at all doses. Typical patterns of response with the four methods of administration are shown in Fig. 2 . With the bolus injections the maximum rate of urinary iron excretion occurred during the first 6h, whereas with the infusions a peak rate of iron excretion was reached after 3-6 h, and was then maintained for the length of the infusion, whether 12 h or 24 h (Fig. 3) . Iron excretion continued at a substantial level for the first few hours after stopping an infusion, but approached base-line values after a further 12 h.
Duration of infusions
In all patients, doubling the infusion time from 12 to 24 h at a constant desferrioxamine dose rate ( Fig. 3; Table 3 ) resulted in twice as much urinary iron excretion. When we compared the effective ness of equal doses given as 12 h or 24 h subcutaneous infusions (Table 3 ) total urinary iron excretion was comparable in patients EP and TT, somewhat better with the 24 h infusion in three patients (MK, VH and AS) and much more effective with the 24 h infusion in patient CC.
Effect of ascorbic acid saturation
In four out of five patients pharmacological doses of oral ascorbic acid (500-1500 mg daily) produced a dramatic increase in urinary iron excretion with 12 h subcutaneous infusions of desferrioxamine (Table 4 ) over a wide range of doses (Fig. 4) . In the fifth patient (RC) there was no change in the dose/urinary iron excretion relationship. The response to ascorbic acid occur red within 24 h in the three patients (MK, VH and AS) in whom this aspect was studied. This reflected rapid restoration of initially very low or undetectable leucocyte and plasma ascorbate con centrations to normal. Initial ascorbate values were not measured in patients RC and TT. In two patients (TT and AS) the effect of ascorbic acid saturation has been maintained for up to 11 months on a dose of 200 mg daily, accompanying repeated self-administration of desferrioxamine infusions at home.
Long-term chelation programmes
In more prolonged use of desferrioxamine (up to 11 months) in regimens based on these studies, doses of 3 g (TT), 2 g (AS) and 2 g (RC) given on 5 nights a week in 12 h subcutaneous infusions have maintained daily urinary iron excretions of 50, 60 and 35 mg respectively. In patient EP, where there was little advantage in using infusions compared with bolus injections, a daily bolus injection of 1-5 g has maintained a daily iron excretion of 9 mg.
Side effects
In most patients mild discomfort and reddening around the subcutaneous injection site occasionally followed the infusions. This was less likely to occur if the needle was inserted deep into the sub cutaneous tissue. No systemic side effects were seen even at the higher rates of infusion. Creatinine clearances, plasma electrolytes and liver-function tests showed no changes before and after the period of infusion. No evidence for cataract formation was detected during the course of the studies, or after regular use of infusions at home over a period of up to 11 months.
Discussion
These studies confirm the previous reports that in most iron-loaded patients prolonged infusion with desferrioxamine is a more efficient way of removing iron than the use of bolus injections. Furthermore, they indicate that this approach is not limited to thalassaemia but appears equally effective in other forms of iron-loading anaemias. Particular atten tion has been paid to both the individual variability and the kinetics of iron removal in order to determine which method of administration is both most efficient and causes least inconvenience to patients. A report that up to 50% of the iron chelated in response to desferrioxamine appears in faeces (Cumming, Millar, Smith & Goldberg, 1969) may mean that our measurement of urinary iron excretion is an underestimate.
While it is clear that occasional patients (e.g. EP) gain little advantage by the use of infusions as compared with bolus injections of desferri oxamine, in most cases a much more substantial negative iron balance can be obtained with a suitable dose of the drug given as a 12 h sub cutaneous infusion, most of which can be given during sleep. In many patients there appears to be no great advantage in using a 24 h continuous infusion. This is because although at a given infusion dose rate doubling the infusion time would double the urinary iron excretion, in many cases with doses up to 4 g doubling the dose given in 12 h, by doubling the infusion dose rate, is very nearly as effective and results in less disturbance of daily routine. This will certainly be the case where increasing the infusion dose rate gives a linear increase in urinary iron excretion (e.g. patient TT, Fig. 1 ). However, where the infusion dose rate is such that the maximum rate of iron excretion is approached increasing the infusion time may be the only way of increasing iron excretion further (e.g. patient CC, Fig. 1 ). These observations, together with the fact that occasional patients do not seem to excrete more with a 12 h infusion as compared with a bolus injection, suggest that it is important to 'tailor-make' individual chelation programmes.
It is also clear from these and previous studies (O 'Brien, 1974; ) that ascorbic acid saturation can increase the output of iron in all the iron-loading states examined, although there was an individual variability, patient RC showing no additional iron excretion. In our study ascorbic acid repletion had a rapid effect within 24 h, in contrast to a previous report which suggested a more delayed response over several days (Wapnick, Lynch, Charlton, Seftel & Bothwell, 1969) . Although there are theoretical risks involved in treating heavily iron-loaded patients with ascorbic acid (Nienhuis, 1977) , the marked increase in iron excretion produced by this approach seems to us to justify its use since these are patients whose lives are threatened by their iron overload. A concern that intensive chelation regimens based on prolonged infusion of desferri oxamine might be associated with increased gastro intestinal iron absorption proved unfounded, as during subcutaneous infusions we found inorganic iron absorption to be reduced (Pippard, Callender, Warner & Weatherall, 1977) . Ocular complications are another potential hazard of long-term ad ministration at high doses and careful ophthalmological surveillance is necessary, particularly in young children, where doses may approach those found to give cataracts in dogs (100 mg day~' kg"" 1 ; Ciba Pharmaceutical Company, 1969) .
The striking variability between iron-loaded patients in their response to desferrioxamine is puzzling and has been the subject of intensive study (Fielding, 1965; Ploem, de Waal, Verloop & Punt, 1966; Hallberg, Hedenberg & Weinfeld, 1966; Balcerzak, Westerman, Heinle & Taylor, 1968; Harker, Funk & Finch, 1968) . Clearly it is not related solely to total body iron load and other factors such as differences in the rates of destruc tion and renal excretion of desferrioxamine, varia tions in secondary metabolism of the chelated compound ferrioxamine (Fielding, 1965) , differ ences in the degree of ineffective erythropoiesis" and variability in intestinal iron absorption may all play a role in producing this variability of response.
The plateau in the urinary iron excretion in response to increasing desferrioxamine doses, which had also been noted with bolus injections (Ciba, 1961) , represents a maximum rate of iron excretion. It varies between individual patients and is increased in most cases by ascorbic acid repletion. It has been suggested that the increased effectiveness of the infusion approach reflects the constant exposure of a rapidly inactivated drug (Peters, Heberle, Schmid & Brunner, 1966 ) to a labile iron pool (Lipschitz, Dugard, Simon, Bothwell & Charlton, 1971; Hershko, Cook & Finch, 1973) and the different patterns of excretion that we have seen after bolus injections and infusions are consistent with this view. It is possible that individual variability may reflect differences in the distribution of the iron load, in the size of the labile pool or in the speed with which this equilibrates with more fixed body iron stores. It is possible that ascorbic acid acts by increasing the size of this labile pool.
These studies have shown that with careful assessment of individual patterns of urinary iron excretion in response to bolus injections or subcutaneous infusions of desferrioxamine, the most efficient use of this expensive drug can be combined with a striking negative iron balance in most patients. Many questions remain to be answered. In particular we need to know whether the negative iron balance produced by sub cutaneous infusion is maintained over a long period. Although our results, which extend over several months, are encouraging we need a much longer period of study. Secondly, studies of the present type must be extended to very early child hood in the hope that iron loading early in life can be prevented. Finally, although it would be imprac tical to start a wide-scale trial of chelating agents used in this way it is certainly of vital importance to find out whether cardiac damage can be reversed by such intensive chelation therapy. Because of the technical difficulties and expense of drugs and pumps this approach to iron chelation cannot be the long-term answer to a disease like thalassaemia, which has such a high incidence in under-developed parts of the world. However, if this regimen can be shown to be of genuine clinical value in reversing cardiac damage or in preventing iron loading early in childhood it might encourage further work in the development of a slow release form of a chelating agent, which, if made on a large scale, might be cheap and effective enough for more widespread use.
